Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hutchison Medipharma Limited
Savolitinib will be administrated 600mg or 400mg once per day (QD). The treatment will be discontinued for the patients who experience disease progression, death or experience unacceptable toxicity, whichever occurs first. A cycle of study treatment will be defined as 21 days of continuous dosing.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1.Fully understood the study and voluntarily signed Informed Consent Form
2.Age \> 18 years
3.Histologically or cytologically documented locally advanced or Metastatic pulmonary sarcomatoid carcinoma (PSC) patients and other Non-small cell lung cancer（NSCLC） with MET Exon 14 mutation who have failed piror systemic therapy(ies), or are unwilling or unable to receive chemotherapy
4.Patient should have measurable disease per RECIST1.1
5.ECOG performance status of 0, or 1
6.Expected survival \> 12 weeks
You may not be if
1.Co-existing malignancy or malignancies diagnosed within the last 3 years other than lung cancer with the exception of adequately treated skin basal cell carcinoma or cervical cancer in situ.
2.Any anti-cancer therapy, including chemotherapy, hormonal therapy, biologic therapy or radiotherapy within 3weeks prior to initiation of study treatment, or received TKI (for ex. EGFR-TKI) treatment within 2 week prior to initiation of study treatment
3.Palliative radiation to bone metastases within 2 weeks prior to the initiation of study treatment
4.Herbal therapy within 1 week prior to the initiation of study treatment
